Sildenafil to Improve Exercise Capacity in People With Thalassemia and Pulmonary Hypertension

• ClinicalTrials.gov Identifier: NCT00872170
• Recruitment Status: Completed
• First Posted: March 31, 2009
• Results First Posted: February 21, 2014
• Last Update Posted: February 21, 2014
• Sponsor: HealthCore-NERI
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
• Information provided by (Responsible Party): HealthCore-NERI

Tracking Information

• First Submitted Date: March 30, 2009
• First Posted Date: March 31, 2009
• Results First Submitted Date: April 24, 2013
• Results First Posted Date: February 21, 2014
• Last Update Posted Date: February 21, 2014
• Study Start Date: March 2009
• Actual Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: January 2, 2014)

Change in Six-minute Walk Test (6MWT) Distance From Baseline to Week 12 Among Sildenafil Group [ Time Frame: Baseline and Week 12 ]

Change in six-minute walk test (6MWT) distance was calculated as 6MWT at week 12 minus 6MWT at baseline.

• Original Primary Outcome Measures (submitted: March 30, 2009): Six-minute walk test (6MWT) distance [ Time Frame: Measured at Week 12 ]

Current Secondary Outcome Measures (submitted: January 2, 2014)

• Change in Tricuspid Regurgitant Jet Velocity (TRV) From Baseline to Week 12 Among Sildenafil Group [ Time Frame: Baseline and Week 12 ]
  Change in tricuspid regurgitant jet velocity (TRV) was calculated as TRV at week 12 minus TRV at baseline. The TRV provides an estimate of pulmonary artery pressure.
• Change in Echo Left Ventricular End Systolic Volume (LVESV) From Baseline to Week 12 Among Sildenafil Group [ Time Frame: Baseline and Week 12 ]
  Change in echo left ventricular end systolic volume (LVESV) was calculated as LVESV at week 12 minus LVESV at baseline.
• Change in Echo Left Ventricular End Diastolic Volume (LVEDV) From Baseline to Week 12 Among Sildenafil Group [ Time Frame: Baseline and Week 12 ]
  Change in echo left ventricular end diastolic volume (LVEDV) was calculated as LVEDV at week 12 minus LVEDV at baseline.
• Change in Plasma Arginine From Baseline to Week 12 Among Sildenafil Group [ Time Frame: Baseline and Week 12 ]
  Change in Plasma Arginine was calculated as Plasma Arginine at week 12 minus Plasma Arginine at baseline.
• Change in Red Blood Cell (RBC) Arginine From Baseline to Week 12 Among Sildenafil Group [ Time Frame: Baseline and Week 12 ]
  Change in Red Blood Cell (RBC) Arginine was calculated as Red Blood Cell (RBC) Arginine at week 12 minus Red Blood Cell (RBC) Arginine at baseline.
• Change in Soluble Platelet Selectin (sP-SELECTIN) From Baseline to Week 12 Among Sildenafil Group [ Time Frame: Baseline and Week 12 ]
  Change in Soluble platelet selectin (sP-SELECTIN) was calculated as sP-SELECTIN at week 12 minus sP-SELECTIN at baseline.
• Change in Lactate Dehydrogenase (LDH) From Baseline to Week 12 Among Sildenafil Group [ Time Frame: Baseline and Week 12 ]
  Change in Lactate dehydrogenase (LDH) was calculated as LDH at week 12 minus LDH at baseline.
• Change in Cell Free Hemoglobin From Baseline to Week 12 Among Sildenafil Group [ Time Frame: Baseline and Week 12 ]
  Change in Cell Free Hemoglobin was calculated as Cell Free Hemoglobin at week 12 minus Cell Free Hemoglobin at baseline.
• Change in Arginase Concentration From Baseline to Week 12 Among Sildenafil Group [ Time Frame: Baseline and Week 12 ]
  Change in Arginase concentration was calculated as Arginase concentration at week 12 minus Arginase concentration at baseline.
• Change in Arginase Activity From Baseline to Week 12 Among Sildenafil Group [ Time Frame: Baseline and Week 12 ]
  Change in Arginase activity was calculated as Arginase activity at week 12 minus Arginase activity at baseline.

Original Secondary Outcome Measures (submitted: March 30, 2009)

• Improved hemodynamics, pulmonary function and structure, hemolysis, arginine-nitric oxide dysregulation, hypercoagulability, inflammation, and cardiac load [ Time Frame: Measured at Week 12 ]
• Characterize PHT in thalassemia with respect to exercise capacity, hemodynamics, pulmonary function and structure, hemolysis, arginine-nitric oxide dysregulation, hypercoagulability, inflammation, and cardiac load [ Time Frame: Measured at Week 12 ]

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Sildenafil to Improve Exercise Capacity in People With Thalassemia and Pulmonary Hypertension
• Official Title: Pilot of Oral Sildenafil for the Treatment of Pulmonary Hypertension in Thalassemia With Comparison to Controls
• Brief Summary: Thalassemia is an inherited blood disorder that can result in mild to severe anemia. Many people with thalassemia also have pulmonary hypertension, which is high blood pressure in the arteries in the lungs. This study will evaluate the safety and effectiveness of the medication sildenafil at reducing blood pressure in the lungs of people with thalassemia and pulmonary hypertension.

Detailed Description

Thalassemia is an inherited blood disorder in which the body makes an abnormal form of hemoglobin-the protein in red blood cells that carries oxygen. A potential complication of thalassemia is pulmonary hypertension, which is a condition characterized by abnormally high blood pressure in the arteries of the lungs. People with thalassemia who have pulmonary hypertension tend to experience more health complications, including shortness of breath and a reduced exercise capacity, than people with thalassemia who do not have pulmonary hypertension. Sildenafil is a medication that is used to treat pulmonary hypertension; however, it has not yet been studied in people with thalassemia. The purpose of this study is to evaluate the safety and effectiveness of sildenafil at reducing blood pressure in the lungs of people who have thalassemia and pulmonary hypertension. Study researchers will also further compare the differences between people with thalassemia who have pulmonary hypertension and those who do not have pulmonary hypertension.

This study will enroll people with thalassemia who have pulmonary hypertension and a control group of people with thalassemia who do not have pulmonary hypertension. People with thalassemia and pulmonary hypertension will attend a baseline study visit at which time they will undergo the following procedures: medical history and medical record review; physical exam; a 6-minute walk test, which will measure how far participants can walk in 6 minutes; an echocardiogram to obtain images of the heart; blood collection; and for females, a urine collection. Participants will then begin taking sildenafil three times a day for 12 weeks. At study visits at Weeks 2, 4, and 8, participants will undergo repeat baseline testing, and some participants will take part in an exhaled nitric oxide test. At Week 12, participants will also undergo lung function testing and a chest magnetic resonance imaging (MRI) procedure.

Participants in the control group will attend one to three study visits at baseline, which will include the same baseline study procedures listed above, plus lung function testing, a chest MRI, a chest computed tomography (CAT) scan, and exhaled nitric oxide testing. They will not receive any medication or have any further study visits.

• Study Type: Interventional
• Study Phase: Phase 2; Phase 3
• Study Design: Allocation: Non-Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• Thalassemia
• Hypertension, Pulmonary

Intervention

Drug: Sildenafil

Participants will receive sildenafil for 12 weeks with the following therapy:

50 mg of oral sildenafil three times a day (TID) increased to 100 mg TID as tolerated in adults and children greater than 50 kg; 1 mg/kg sildenafil TID without dose escalation in children less than 50 kg

Other Names:

• Revatio
• Viagra

Study Arms

• Active Comparator: Intervention
  Participants with thalassemia who have pulmonary hypertension will receive sildenafil for 12 weeks.
  Intervention: Drug: Sildenafil
• No Intervention: Control
  Participants with thalassemia who do not have pulmonary hypertension will be part of a control group and will only be undergoing screening/baseline assessments.

• Publications *: Morris CR, Kim HY, Wood J, Porter JB, Klings ES, Trachtenberg FL, Sweeters N, Olivieri NF, Kwiatkowski JL, Virzi L, Singer ST, Taher A, Neufeld EJ, Thompson AA, Sachdev V, Larkin S, Suh JH, Kuypers FA, Vichinsky EP; Thalassemia Clinical Research Network. Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. Haematologica. 2013 Sep;98(9):1359-67. doi: 10.3324/haematol.2012.082065. Epub 2013 Apr 12.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: June 29, 2011): 27
• Original Estimated Enrollment (submitted: March 30, 2009): 24
• Actual Study Completion Date: November 2010
• Actual Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria for All Participants:

• Alpha, beta, or E-beta thalassemia confirmed by hemoglobin (Hb)-electrophoresis or molecular diagnosis

Inclusion Criteria for Participants with Pulmonary Hypertension:

• Pulmonary hypertension, defined as a tricuspid regurgitant jet (TRjet) velocity by Doppler echocardiography greater than 2.5 m/s

Inclusion Criteria for Participants without Pulmonary Hypertension:

• Lack of pulmonary hypertension, defined as TRjet velocity by Doppler echocardiography less than 2.5 m/s

Exclusion Criteria:

• Pregnant or breastfeeding
• Hypersensitivity to arginine or sildenafil, based on prior use

• Any of the following medical conditions:

  1. Severe kidney insufficiency, defined as use of hemodialysis or serum creatinine at levels greater than 2.5 mg/dL at the time of screening
  2. Cardiac disease with adjustment of cardiac medications in the 60 days before study entry
  3. Symptomatic coronary artery disease, as indicated by a history of chest pain, angina, claudication, or surgery to treat coronary artery disease in the 1 year before study entry
  4. Stroke, defined as a new focal neurological deficit lasting more than 24 hours in the 45 days before study entry
  5. New diagnosis of pulmonary embolism by ventilation-perfusion scan, angiography, or any other technique in the 90 days before study entry
  6. History of retinal detachment or retinal hemorrhage in the 180 days before study entry
  7. Use of nitrate-based vasodilators, prostacyclin (inhaled, subcutaneous, or intravenous), endothelin antagonists, or any other medication for pulmonary hypertension
  8. Acute asthma exacerbation requiring use of prednisone in the 60 days before study entry
  9. Initiation or dosage increase of calcium channel blockers in the 30 days before study entry
  10. Initiation of any other cardiac or pulmonary medication in the 90 days before study entry
• Presence of any other condition, which in the opinion of the investigator, would make the person unsuitable for enrollment or could interfere with compliance in the study, including but not limited to alcohol or drug abuse
• No measurable TRjet on Doppler echocardiography (i.e., presence of pulmonary hypertension cannot be confirmed or ruled out)

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 7 Years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT00872170
• Other Study ID Numbers: 638; U01HL065238 ( U.S. NIH Grant/Contract )
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: HealthCore-NERI
• Original Responsible Party: NHLBI
• Current Study Sponsor: HealthCore-NERI
• Original Study Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
• Collaborators: National Heart, Lung, and Blood Institute (NHLBI)

Investigators

• Principal Investigator: Ellis Neufeld, MD, PhD; Boston Children's Hospital
• Study Chair: Claudia Morris, MD; Children's Hospital and Research Institute Oakland
• Principal Investigator: Charles Quinn, MD; University of Texas, Southwestern Medical Center at Dallas
• Principal Investigator: Patricia Giardina, MD; Weill Medical College of Cornell
• Principal Investigator: Janet Kwiatkowski, MD; Children's Hospital of Philadelphia
• Principal Investigator: Nancy Olivieri, MD; Toronto General Hospital
• Principal Investigator: John Porter, MD; University College, London
• Principal Investigator: Ali Taher, MD; American University of Beirut Medical Center- Lebannon

• PRS Account: HealthCore-NERI
• Verification Date: January 2014